Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and accounts for more than 60–80% of all cases of dementia. Loss of pyramidal neurons, extracellular amyloid beta (Abeta) accumulated senile plaques, and neurofibrillary tangles that contain hyperphosphorylated tau constitute the main pathological alterations in AD.
Synaptic dysfunction and extrasynaptic N-methyl-D-aspartate receptor (NMDAR) hyperactivation contributes to excitotoxicity in patients with AD. Amyloid precursor protein (APP) and Abeta promoted neurodegeneration develop through the activation of protein kinase signaling cascade in AD. Furthermore, ultimate neuronal death in AD is under control of protein kinases-related signaling pathways. In this chapter, critical check-points within the cross-talk between neuron and protein kinases have been defined regarding the initiation and progression of AD. In this context, amyloid cascade hypothesis, neuroinflammation, oxidative stress, granulovacuolar degeneration, loss of Wnt signaling, Abeta-related synaptic alterations, prolonged calcium ions overload and NMDAR-related synaptotoxicity, damage signals hypothesis and type-3 diabetes are discussed briefly.
In addition to clinical perspective of AD pathology, recommendations that might be effective in the treatment of AD patients have been reviewed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abbott MA, Wells DG, Fallon JR. The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J Neurosci. 1999;19:7300–8.
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O’Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000;21:383–421. https://doi.org/10.1016/s0197-4580(00)00124-x.
Alberdi E, Sánchez-Gómez MV, Cavaliere F, Pérez-Samartín A, Zugaza JL, Trullas R, Domercq M, Matute C. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium. 2010;47:264–72. https://doi.org/10.1016/j.ceca.2009.12.010.
Alberdi E, Wyssenbach A, Alberdi M, Sánchez-Gómez MV, Cavaliere F, Rodríguez JJ, Verkhratsky A, Matute C. Ca(2+) -dependent endoplasmic reticulum stress correlates with astrogliosis in oligomeric amyloid β-treated astrocytes and in a model of Alzheimer’s disease. Aging Cell. 2013;12:292–302. https://doi.org/10.1111/acel.12054.
Alzheimer’s Association. 2014 Alzheimer’s disease facts and figures. Alzheimers Dement. 2014;10:e47–92. https://doi.org/10.1016/j.jalz.2014.02.001.
Amadoro G, Ciotti MT, Costanzi M, Cestari V, Calissano P, Canu N. NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc Natl Acad Sci U S A. 2006;103:2892–7. https://doi.org/10.1073/pnas.0511065103.
An W-L, Cowburn RF, Li L, Braak H, Alafuzoff I, Iqbal K, Iqbal I-G, Winblad B, Pei J-J. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer’s disease. Am J Pathol. 2003;163:591–607. https://doi.org/10.1016/S0002-9440(10)63687-5.
An X-Q, Xi W, Gu C-Y, Huang X. Complement protein C5a enhances the β-amyloid-induced neuro-inflammatory response in microglia in Alzheimer’s disease. Med Sci (Paris). 2018;34 Focus issue F1:116–20. https://doi.org/10.1051/medsci/201834f120.
Andreasson K. Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat. 2010;91:104–12. https://doi.org/10.1016/j.prostaglandins.2009.04.003.
Anguita E, Villalobo A. Src-family tyrosine kinases and the Ca2+ signal. Biochim Biophys Acta, Mol Cell Res. 2017;1864:915–32. https://doi.org/10.1016/j.bbamcr.2016.10.022.
Annadurai N, Agrawal K, Džubák P, Hajdúch M, Das V. Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer’s disease. Cell Mol Life Sci. 2017;74:4159–69. https://doi.org/10.1007/s00018-017-2574-1.
Arrázola MS, Varela-Nallar L, Colombres M, Toledo EM, Cruzat F, Pavez L, Assar R, Aravena A, González M, Montecino M, Maass A, Martínez S, Inestrosa NC. Calcium/calmodulin-dependent protein kinase type IV is a target gene of the Wnt/beta-catenin signaling pathway. J Cell Physiol. 2009;221:658–67. https://doi.org/10.1002/jcp.21902.
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42:631–9. https://doi.org/10.1212/wnl.42.3.631.
Balaraman Y, Limaye AR, Levey AI, Srinivasan S. Glycogen synthase kinase 3beta and Alzheimer’s disease: pathophysiological and therapeutic significance. Cell Mol Life Sci. 2006;63:1226–35. https://doi.org/10.1007/s00018-005-5597-y.
Bamberger ME, Landreth GE. Microglial interaction with beta-amyloid: implications for the pathogenesis of Alzheimer’s disease. Microsc Res Tech. 2001;54:59–70. https://doi.org/10.1002/jemt.1121.
Bartl J, Monoranu C-M, Wagner A-K, Kolter J, Riederer P, Grünblatt E. Alzheimer’s disease and type 2 diabetes: two diseases, one common link? World J Biol Psychiatry. 2013;14:233–40. https://doi.org/10.3109/15622975.2011.650204.
Benarroch EE. Brain-derived neurotrophic factor: regulation, effects, and potential clinical relevance. Neurology. 2015;84:1693–704. https://doi.org/10.1212/WNL.0000000000001507.
Berridge MJ. Calcium hypothesis of Alzheimer’s disease. Pflugers Arch. 2010;459:441–9. https://doi.org/10.1007/s00424-009-0736-1.
Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci. 2008;31:454–63. https://doi.org/10.1016/j.tins.2008.06.005.
Bilousova T, Miller CA, Poon WW, Vinters HV, Corrada M, Kawas C, Hayden EY, Teplow DB, Glabe C, Albay R, Cole GM, Teng E, Gylys KH. Synaptic amyloid-β oligomers precede p-Tau and differentiate high pathology control cases. Am J Pathol. 2016;186:185–98. https://doi.org/10.1016/j.ajpath.2015.09.018.
Birnbaum JH, Bali J, Rajendran L, Nitsch RM, Tackenberg C. Calcium flux-independent NMDA receptor activity is required for Aβ oligomer-induced synaptic loss. Cell Death Dis. 2015;6:e1791. https://doi.org/10.1038/cddis.2015.160.
Biswas SC, Shi Y, Vonsattel J-PG, Leung CL, Troy CM, Greene LA. Bim is elevated in Alzheimer’s disease neurons and is required for beta-amyloid-induced neuronal apoptosis. J Neurosci. 2007;27:893–900. https://doi.org/10.1523/JNEUROSCI.3524-06.2007.
Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Müller F-J, Loring JF, Yamasaki TR, Poon WW, Green KN, LaFerla FM. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A. 2009;106:13594–9. https://doi.org/10.1073/pnas.0901402106.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59. https://doi.org/10.1007/bf00308809.
Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer’s disease beta-peptide. J Exp Med. 1998;188:431–8. https://doi.org/10.1084/jem.188.3.431.
Broe M, Shepherd CE, Milward EA, Halliday GM. Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol. 2001;101:616–24. https://doi.org/10.1007/s004010000337.
Browne TC, McQuillan K, McManus RM, O’Reilly J-A, Mills KHG, Lynch MA. IFN-γ production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer’s disease. J Immunol. 2013;190:2241–51. https://doi.org/10.4049/jimmunol.1200947.
Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol. 1992;23:1–34. https://doi.org/10.1016/s1054-3589(08)60961-8.
Buckley KM, Melikian HE, Provoda CJ, Waring MT. Regulation of neuronal function by protein trafficking: a role for the endosomal pathway. J Physiol Lond. 2000;525(Pt 1):11–9. https://doi.org/10.1111/j.1469-7793.2000.t01-2-00011.x.
Caccamo A, Branca C, Piras IS, Ferreira E, Huentelman MJ, Liang WS, Readhead B, Dudley JT, Spangenberg EE, Green KN, Belfiore R, Winslow W, Oddo S. Necroptosis activation in Alzheimer’s disease. Nat Neurosci. 2017;20:1236–46. https://doi.org/10.1038/nn.4608.
Caccamo A, Belfiore R, Oddo S. Genetically reducing mTOR signaling rescues central insulin dysregulation in a mouse model of Alzheimer’s disease. Neurobiol Aging. 2018;68:59–67. https://doi.org/10.1016/j.neurobiolaging.2018.03.032.
Cai Z, Yan L-J, Li K, Quazi SH, Zhao B. Roles of AMP-activated protein kinase in Alzheimer’s disease. NeuroMolecular Med. 2012;14:1–14. https://doi.org/10.1007/s12017-012-8173-2.
Calò L, Cinque C, Patanè M, Schillaci D, Battaglia G, Melchiorri D, Nicoletti F, Bruno V. Interaction between ephrins/Eph receptors and excitatory amino acid receptors: possible relevance in the regulation of synaptic plasticity and in the pathophysiology of neuronal degeneration. J Neurochem. 2006;98:1–10. https://doi.org/10.1111/j.1471-4159.2006.03844.x.
Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. 2009;158:983–94. https://doi.org/10.1016/j.neuroscience.2008.06.025.
Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med. 2002;8:1390–7. https://doi.org/10.1038/nm1202-793.
Cerpa W, Godoy JA, Alfaro I, Farías GG, Metcalfe MJ, Fuentealba R, Bonansco C, Inestrosa NC. Wnt-7a modulates the synaptic vesicle cycle and synaptic transmission in hippocampal neurons. J Biol Chem. 2008;283:5918–27. https://doi.org/10.1074/jbc.M705943200.
Chan SHH, Wu C-WJ, Chang AYW, Hsu K-S, Chan JYH. Transcriptional upregulation of brain-derived neurotrophic factor in rostral ventrolateral medulla by angiotensin II: significance in superoxide homeostasis and neural regulation of arterial pressure. Circ Res. 2010;107:1127–39. https://doi.org/10.1161/CIRCRESAHA.110.225573.
Chang RCC, Wong AKY, Ng H-K, Hugon J. Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer’s disease. Neuroreport. 2002;13:2429–32. https://doi.org/10.1097/00001756-200212200-00011.
Chaput D, Kirouac LH, Bell-Temin H, Stevens SM, Padmanabhan J. SILAC-based proteomic analysis to investigate the impact of amyloid precursor protein expression in neuronal-like B103 cells. Electrophoresis. 2012;33:3728–37. https://doi.org/10.1002/elps.201200251.
Chaudhury AR, Gerecke KM, Wyss JM, Morgan DG, Gordon MN, Carroll SL. Neuregulin-1 and erbB4 immunoreactivity is associated with neuritic plaques in Alzheimer disease brain and in a transgenic model of Alzheimer disease. J Neuropathol Exp Neurol. 2003;62:42–54. https://doi.org/10.1093/jnen/62.1.42.
Chen HC, Guan JL. Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A. 1994;91:10148–52. https://doi.org/10.1073/pnas.91.21.10148.
Chen T-J, Wang D-C, Chen S-S. Amyloid-beta interrupts the PI3K-Akt-mTOR signaling pathway that could be involved in brain-derived neurotrophic factor-induced Arc expression in rat cortical neurons. J Neurosci Res. 2009;87:2297–307. https://doi.org/10.1002/jnr.22057.
Chen L, Xu B, Liu L, Luo Y, Yin J, Zhou H, Chen W, Shen T, Han X, Huang S. Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. Lab Investig. 2010;90:762–73. https://doi.org/10.1038/labinvest.2010.36.
Chen J, Sun Z, Jin M, Tu Y, Wang S, Yang X, Chen Q, Zhang X, Han Y, Pi R. Inhibition of AGEs/RAGE/Rho/ROCK pathway suppresses non-specific neuroinflammation by regulating BV2 microglial M1/M2 polarization through the NF-κB pathway. J Neuroimmunol. 2017;305:108–14. https://doi.org/10.1016/j.jneuroim.2017.02.010.
Cheng D, Hoogenraad CC, Rush J, Ramm E, Schlager MA, Duong DM, Xu P, Wijayawardana SR, Hanfelt J, Nakagawa T, Sheng M, Peng J. Relative and absolute quantification of postsynaptic density proteome isolated from rat forebrain and cerebellum. Mol Cell Proteomics. 2006;5:1158–70. https://doi.org/10.1074/mcp.D500009-MCP200.
Cheng X, Shen D, Samie M, Xu H. Mucolipins: intracellular TRPML1-3 channels. FEBS Lett. 2010;584:2013–21. https://doi.org/10.1016/j.febslet.2009.12.056.
Chin J, Palop JJ, Yu G-Q, Kojima N, Masliah E, Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci. 2004;24:4692–7. https://doi.org/10.1523/JNEUROSCI.0277-04.2004.
Chin J, Palop JJ, Puoliväli J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer’s disease. J Neurosci. 2005;25:9694–703. https://doi.org/10.1523/JNEUROSCI.2980-05.2005.
Chong ZZ, Li F, Maiese K. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol. 2005;75:207–46. https://doi.org/10.1016/j.pneurobio.2005.02.004.
Chong ZZ, Li F, Maiese K. Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. Cell Signal. 2007;19:1150–62. https://doi.org/10.1016/j.cellsig.2006.12.009.
Chong ZZ, Shang YC, Wang S, Maiese K. SIRT1: new avenues of discovery for disorders of oxidative stress. Expert Opin Ther Targets. 2012;16:167–78. https://doi.org/10.1517/14728222.2012.648926.
Christie JM, Wenthold RJ, Monaghan DT. Insulin causes a transient tyrosine phosphorylation of NR2A and NR2B NMDA receptor subunits in rat hippocampus. J Neurochem. 1999;72:1523–8. https://doi.org/10.1046/j.1471-4159.1999.721523.x.
Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry. 2003;42:12749–60. https://doi.org/10.1021/bi030029q.
Cirrito JR, Kang J-E, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42–51. https://doi.org/10.1016/j.neuron.2008.02.003.
Cissé M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, Ho K, Yu G-Q, Mucke L. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature. 2011;469:47–52. https://doi.org/10.1038/nature09635.
Columba-Cabezas S, Serafini B, Ambrosini E, Sanchez M, Penna G, Adorini L, Aloisi F. Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J Neuroimmunol. 2002;130:10–21. https://doi.org/10.1016/s0165-5728(02)00170-4.
Conant K, Wang Y, Szklarczyk A, Dudak A, Mattson MP, Lim ST. Matrix metalloproteinase-dependent shedding of intercellular adhesion molecule-5 occurs with long-term potentiation. Neuroscience. 2010;166:508–21. https://doi.org/10.1016/j.neuroscience.2009.12.061.
Cooper NR, Bradt BM, O’Barr S, Yu JX. Focal inflammation in the brain: role in Alzheimer’s disease. Immunol Res. 2000;21:159–65. https://doi.org/10.1385/IR:21:2-3:159.
Cota D, Proulx K, Smith KAB, Kozma SC, Thomas G, Woods SC, Seeley RJ. Hypothalamic mTOR signaling regulates food intake. Science. 2006;312:927–30. https://doi.org/10.1126/science.1124147.
Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum Mol Genet. 2010;19:R12–20. https://doi.org/10.1093/hmg/ddq160.
Cui Y, Ma S, Zhang C, Cao W, Liu M, Li D, Lv P, Xing Q, Qu R, Yao N, Yang B, Guan F. Human umbilical cord mesenchymal stem cells transplantation improves cognitive function in Alzheimer’s disease mice by decreasing oxidative stress and promoting hippocampal neurogenesis. Behav Brain Res. 2017;320:291–301. https://doi.org/10.1016/j.bbr.2016.12.021.
Culberson JW. Clinical aspects of glucose metabolism and chronic disease. Prog Mol Biol Transl Sci. 2017;146:1–11. https://doi.org/10.1016/bs.pmbts.2016.12.011.
Curcio-Morelli C, Charles FA, Micsenyi MC, Cao Y, Venugopal B, Browning MF, Dobrenis K, Cotman SL, Walkley SU, Slaugenhaupt SA. Macroautophagy is defective in mucolipin-1-deficient mouse neurons. Neurobiol Dis. 2010;40:370–7. https://doi.org/10.1016/j.nbd.2010.06.010.
Dalva MB, Takasu MA, Lin MZ, Shamah SM, Hu L, Gale NW, Greenberg ME. EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell. 2000;103:945–56. https://doi.org/10.1016/s0092-8674(00)00197-5.
Danysz W, Parsons CG. Alzheimer’s disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br J Pharmacol. 2012;167:324–52. https://doi.org/10.1111/j.1476-5381.2012.02057.x.
Decker H, Jürgensen S, Adrover MF, Brito-Moreira J, Bomfim TR, Klein WL, Epstein AL, De Felice FG, Jerusalinsky D, Ferreira ST. N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer’s toxic amyloid-β peptide oligomers. J Neurochem. 2010;115:1520–9. https://doi.org/10.1111/j.1471-4159.2010.07058.x.
De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem. 2007;282:11590–601. https://doi.org/10.1074/jbc.M607483200.
De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, Chen-Dodson E, Kinney GG, Klein WL. Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging. 2008;29:1334–47. https://doi.org/10.1016/j.neurobiolaging.2007.02.029.
de la Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer’s disease. Drugs. 2012a;72:49–66. https://doi.org/10.2165/11597760-000000000-00000.
de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res. 2012b;9:35–66. https://doi.org/10.2174/156720512799015037.
de la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008;2:1101–13. https://doi.org/10.1177/193229680800200619.
Dello Russo C, Lisi L, Tringali G, Navarra P. Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem Pharmacol. 2009;78:1242–51. https://doi.org/10.1016/j.bcp.2009.06.097.
De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer’s disease. Subcell Biochem. 2012;65:329–52. https://doi.org/10.1007/978-94-007-5416-4_14.
Di Domenico F, Barone E, Perluigi M, Butterfield DA. The triangle of death in Alzheimer’s disease brain: the aberrant cross-talk among energy metabolism, mammalian target of rapamycin signaling, and protein homeostasis revealed by redox proteomics. Antioxid Redox Signal. 2017;26:364–87. https://doi.org/10.1089/ars.2016.6759.
Dong X-P, Wang X, Xu H. TRP channels of intracellular membranes. J Neurochem. 2010;113:313–28. https://doi.org/10.1111/j.1471-4159.2010.06626.x.
Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, Yan SD. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nat Med. 2008;14:1097–105. https://doi.org/10.1038/nm.1868.
Du H, Guo L, Wu X, Sosunov AA, McKhann GM, Chen JX, Yan SS. Cyclophilin D deficiency rescues Aβ-impaired PKA/CREB signaling and alleviates synaptic degeneration. Biochim Biophys Acta. 2014;1842:2517–27. https://doi.org/10.1016/j.bbadis.2013.03.004.
Du F, Yu Q, Yan S, Hu G, Lue L-F, Walker DG, Wu L, Yan SF, Tieu K, Yan SS. PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer’s disease. Brain. 2017;140:3233–51. https://doi.org/10.1093/brain/awx258.
El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, Freeman MW, Luster AD. CD36 mediates the innate host response to beta-amyloid. J Exp Med. 2003;197:1657–66. https://doi.org/10.1084/jem.20021546.
Engin AB, Engin ED, Karakus R, Aral A, Gulbahar O, Engin A. N-Methyl-D aspartate receptor-mediated effect on glucose transporter-3 levels of high glucose exposed-SH-SY5Y dopaminergic neurons. Food Chem Toxicol. 2017;109:465–71. https://doi.org/10.1016/j.fct.2017.09.038.
Farías GG, Vallés AS, Colombres M, Godoy JA, Toledo EM, Lukas RJ, Barrantes FJ, Inestrosa NC. Wnt-7a induces presynaptic colocalization of alpha 7-nicotinic acetylcholine receptors and adenomatous polyposis coli in hippocampal neurons. J Neurosci. 2007;27:5313–25. https://doi.org/10.1523/JNEUROSCI.3934-06.2007.
Ferreiro E, Oliveira CR, Pereira C. Involvement of endoplasmic reticulum Ca2+ release through ryanodine and inositol 1,4,5-triphosphate receptors in the neurotoxic effects induced by the amyloid-beta peptide. J Neurosci Res. 2004;76:872–80. https://doi.org/10.1002/jnr.20135.
Ferrer I. Stress kinases involved in tau phosphorylation in Alzheimer’s disease, tauopathies and APP transgenic mice. Neurotox Res. 2004;6:469–75. https://doi.org/10.1007/bf03033283.
Ferrer I, Blanco R, Carmona M, Puig B. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm (Vienna). 2001;108:1397–415. https://doi.org/10.1007/s007020100016.
Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribé E, Dalfó E, Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer’s disease and tauopathies. Curr Alzheimer Res. 2005;2:3–18. https://doi.org/10.2174/1567205052772713.
Fleitas C, Piñol-Ripoll G, Marfull P, Rocandio D, Ferrer I, Rampon C, Egea J, Espinet C. proBDNF is modified by advanced glycation end products in Alzheimer’s disease and causes neuronal apoptosis by inducing p75 neurotrophin receptor processing. Mol Brain. 2018;11:68. https://doi.org/10.1186/s13041-018-0411-6.
Fodero-Tavoletti MT, Cappai R, McLean CA, Pike KE, Adlard PA, Cowie T, Connor AR, Masters CL, Rowe CC, Villemagne VL. Amyloid imaging in Alzheimer’s disease and other dementias. Brain Imaging Behav. 2009;3:246–61. https://doi.org/10.1007/s11682-009-9067-2.
Folke J, Pakkenberg B, Brudek T. Impaired Wnt signaling in the prefrontal cortex of Alzheimer’s disease. Mol Neurobiol. 2019;56:873–91. https://doi.org/10.1007/s12035-018-1103-z.
Franco R, Martínez-Pinilla E, Navarro G, Zamarbide M. Potential of GPCRs to modulate MAPK and mTOR pathways in Alzheimer’s disease. Prog Neurobiol. 2017;149–150:21–38. https://doi.org/10.1016/j.pneurobio.2017.01.004.
Funk KE, Mrak RE, Kuret J. Granulovacuolar degeneration (GVD) bodies of Alzheimer’s disease (AD) resemble late-stage autophagic organelles. Neuropathol Appl Neurobiol. 2011;37:295–306. https://doi.org/10.1111/j.1365-2990.2010.01135.x.
Galan-Moya EM, Le Guelte A, Lima Fernandes E, Thirant C, Dwyer J, Bidere N, Couraud P-O, Scott MGH, Junier M-P, Chneiweiss H, Gavard J. Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway. EMBO Rep. 2011;12:470–6. https://doi.org/10.1038/embor.2011.39.
Geng J, Klionsky DJ. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. “Protein modifications: beyond the usual suspects” review series. EMBO Rep. 2008;9:859–64. https://doi.org/10.1038/embor.2008.163.
Giannakopoulos P, Gold G, von Gunten A, Hof PR, Bouras C. Pathological substrates of cognitive decline in Alzheimer’s disease. Front Neurol Neurosci. 2009;24:20–9. https://doi.org/10.1159/000197881.
Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science. 2006;314:777–81. https://doi.org/10.1126/science.1132814.
Goldsbury C, Mocanu M-M, Thies E, Kaether C, Haass C, Keller P, Biernat J, Mandelkow E, Mandelkow E-M. Inhibition of APP trafficking by tau protein does not increase the generation of amyloid-beta peptides. Traffic. 2006;7:873–88. https://doi.org/10.1111/j.1600-0854.2006.00434.x.
Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156:15–20. https://doi.org/10.1016/s0002-9440(10)64700-1.
Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer’s disease. Acta Neuropathol. 2010;119:523–41. https://doi.org/10.1007/s00401-010-0679-9.
Gouras GK, Willén K, Faideau M. The inside-out amyloid hypothesis and synapse pathology in Alzheimer’s disease. Neurodegener Dis. 2014;13:142–6. https://doi.org/10.1159/000354776.
Greenfield JP, Tsai J, Gouras GK, Hai B, Thinakaran G, Checler F, Sisodia SS, Greengard P, Xu H. Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc Natl Acad Sci U S A. 1999;96:742–7. https://doi.org/10.1073/pnas.96.2.742.
Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O’Connor R, O’Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology. J Neurochem. 2005;93:105–17. https://doi.org/10.1111/j.1471-4159.2004.02949.x.
Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913–7. https://doi.org/10.1073/pnas.83.13.4913.
Gu GJ, Wu D, Lund H, Sunnemark D, Kvist AJ, Milner R, Eckersley S, Nilsson LNG, Agerman K, Landegren U, Kamali-Moghaddam M. Elevated MARK2-dependent phosphorylation of Tau in Alzheimer’s disease. J Alzheimers Dis. 2013;33:699–713. https://doi.org/10.3233/JAD-2012-121357.
Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry. 2007;78:461–4. https://doi.org/10.1136/jnnp.2006.100529.
Haass C, Mandelkow E. Fyn-tau-amyloid: a toxic triad. Cell. 2010;142:356–8. https://doi.org/10.1016/j.cell.2010.07.032.
Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9:857–65. https://doi.org/10.1038/ni.1636.
Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer’s disease. J Cell Biol. 2018;217:459–72. https://doi.org/10.1083/jcb.201709069.
Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110:177–89. https://doi.org/10.1016/s0092-8674(02)00833-4.
Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11:682–96. https://doi.org/10.1038/nrn2911.
Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002;5:405–14. https://doi.org/10.1038/nn835.
Hartmann T, Bieger SC, Brühl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, Beyreuther K. Distinct sites of intracellular production for Alzheimer’s disease A beta40/42 amyloid peptides. Nat Med. 1997;3:1016–20. https://doi.org/10.1038/nm0997-1016.
Hayashi K, Ohshima T, Mikoshiba K. Pak1 is involved in dendrite initiation as a downstream effector of Rac1 in cortical neurons. Mol Cell Neurosci. 2002;20:579–94. https://doi.org/10.1006/mcne.2002.1144.
He R, Peng J, Yuan P, Xu F, Wei W. Divergent roles of BECN1 in LC3 lipidation and autophagosomal function. Autophagy. 2015;11:740–7. https://doi.org/10.1080/15548627.2015.1034404.
Henriksen EJ, Dokken BB. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets. 2006;7:1435–41. https://doi.org/10.2174/1389450110607011435.
Hernandez F, Lucas JJ, Avila J. GSK3 and tau: two convergence points in Alzheimer’s disease. J Alzheimers Dis. 2013;33(Suppl 1):S141–4. https://doi.org/10.3233/JAD-2012-129025.
Ho GJ, Drego R, Hakimian E, Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer’s disease. Curr Drug Targets Inflamm Allergy. 2005a;4:247–56. https://doi.org/10.2174/1568010053586237.
Ho GJ, Hashimoto M, Adame A, Izu M, Alford MF, Thal LJ, Hansen LA, Masliah E. Altered p59Fyn kinase expression accompanies disease progression in Alzheimer’s disease: implications for its functional role. Neurobiol Aging. 2005b;26:625–35. https://doi.org/10.1016/j.neurobiolaging.2004.06.016.
Hong YK, Lee S, Park SH, Lee JH, Han SY, Kim ST, Kim Y-K, Jeon S, Koo B-S, Cho KS. Inhibition of JNK/dFOXO pathway and caspases rescues neurological impairments in Drosophila Alzheimer’s disease model. Biochem Biophys Res Commun. 2012;419:49–53. https://doi.org/10.1016/j.bbrc.2012.01.122.
Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer’s disease. J Neurochem. 2008;104:1433–9. https://doi.org/10.1111/j.1471-4159.2007.05194.x.
Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity. 1996;4:387–96. https://doi.org/10.1016/s1074-7613(00)80252-6.
Hu R, Wei P, Jin L, Zheng T, Chen W-Y, Liu X-Y, Shi X-D, Hao J-R, Sun N, Gao C. Overexpression of EphB2 in hippocampus rescues impaired NMDA receptors trafficking and cognitive dysfunction in Alzheimer model. Cell Death Dis. 2017;8:e2717. https://doi.org/10.1038/cddis.2017.140.
Hugon J, Mouton-Liger F, Dumurgier J, Paquet C. PKR involvement in Alzheimer’s disease. Alzheimers Res Ther. 2017;9:83. https://doi.org/10.1186/s13195-017-0308-0.
Imahori K, Hoshi M, Ishiguro K, Sato K, Takahashi M, Shiurba R, Yamaguchi H, Takashima A, Uchida T. Possible role of tau protein kinases in pathogenesis of Alzheimer’s disease. Neurobiol Aging. 1998;19:S93–8. https://doi.org/10.1016/s0197-4580(98)00025-6.
Inestrosa NC, Varela-Nallar L. Wnt signaling in the nervous system and in Alzheimer’s disease. J Mol Cell Biol. 2014;6:64–74. https://doi.org/10.1093/jmcb/mjt051.
Ishizuka Y, Hanamura K. Drebrin in Alzheimer’s Disease. Adv Exp Med Biol. 2017;1006:203–23. https://doi.org/10.1007/978-4-431-56550-5_12.
Ishizuka Y, Shimizu H, Takagi E, Kato M, Yamagata H, Mikuni M, Shirao T. Histone deacetylase mediates the decrease in drebrin cluster density induced by amyloid beta oligomers. Neurochem Int. 2014;76:114–21. https://doi.org/10.1016/j.neuint.2014.07.005.
Itagaki S, McGeer PL, Akiyama H. Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer’s disease brain tissue. Neurosci Lett. 1988;91:259–64. https://doi.org/10.1016/0304-3940(88)90690-8.
Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell. 2010;142:387–97. https://doi.org/10.1016/j.cell.2010.06.036.
Jackson RJ, Rudinskiy N, Herrmann AG, Croft S, Kim JM, Petrova V, Ramos-Rodriguez JJ, Pitstick R, Wegmann S, Garcia-Alloza M, Carlson GA, Hyman BT, Spires-Jones TL. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer’s disease. Eur J Neurosci. 2016;44:3056–66. https://doi.org/10.1111/ejn.13442.
Jaeger PA, Wyss-Coray T. All-you-can-eat: autophagy in neurodegeneration and neuroprotection. Mol Neurodegener. 2009;4:16. https://doi.org/10.1186/1750-1326-4-16.
Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004;53:474–81. https://doi.org/10.2337/diabetes.53.2.474.
Jiang T, Yu J-T, Zhu X-C, Tan M-S, Wang H-F, Cao L, Zhang Q-Q, Shi J-Q, Gao L, Qin H, Zhang Y-D, Tan L. Temsirolimus promotes autophagic clearance of amyloid-β and provides protective effects in cellular and animal models of Alzheimer’s disease. Pharmacol Res. 2014;81:54–63. https://doi.org/10.1016/j.phrs.2014.02.008.
Julien C, Tremblay C, Emond V, Lebbadi M, Salem N, Bennett DA, Calon F. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol. 2009;68:48–58. https://doi.org/10.1097/NEN.0b013e3181922348.
Kamat PK, Kalani A, Rai S, Swarnkar S, Tota S, Nath C, Tyagi N. Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of Alzheimer’s disease: understanding the therapeutics strategies. Mol Neurobiol. 2016;53:648–61. https://doi.org/10.1007/s12035-014-9053-6.
Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925–37. https://doi.org/10.1016/s0896-6273(03)00124-7.
Kandimalla R, Thirumala V, Reddy PH. Is Alzheimer’s disease a type 3 diabetes? A critical appraisal. Biochim Biophys Acta Mol basis Dis. 2017;1863:1078–89. https://doi.org/10.1016/j.bbadis.2016.08.018.
Kang J-Q, Chong ZZ, Maiese K. Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity. J Neurosci Res. 2003;74:37–51. https://doi.org/10.1002/jnr.10740.
Kassem S, Gaud G, Bernard I, Benamar M, Dejean AS, Liblau R, Fournié GJ, Colacios C, Malissen B, Saoudi A. A natural variant of the T cell receptor-signaling molecule Vav1 reduces both effector T cell functions and susceptibility to neuroinflammation. PLoS Genet. 2016;12:e1006185. https://doi.org/10.1371/journal.pgen.1006185.
Kim D-H, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110:163–75. https://doi.org/10.1016/s0092-8674(02)00808-5.
Kim HJ, Soyombo AA, Tjon-Kon-Sang S, So I, Muallem S. The Ca(2+) channel TRPML3 regulates membrane trafficking and autophagy. Traffic. 2009;10:1157–67. https://doi.org/10.1111/j.1600-0854.2009.00924.x.
Kim J, Kundu M, Viollet B, Guan K-L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132–41. https://doi.org/10.1038/ncb2152.
Kim B, Figueroa-Romero C, Pacut C, Backus C, Feldman EL. Insulin resistance prevents AMPK-induced tau dephosphorylation through Akt-mediated increase in AMPKSer-485 phosphorylation. J Biol Chem. 2015;290:19146–57. https://doi.org/10.1074/jbc.M115.636852.
Kirouac L, Rajic AJ, Cribbs DH, Padmanabhan J. Activation of Ras-ERK signaling and GSK-3 by amyloid precursor protein and amyloid beta facilitates neurodegeneration in Alzheimer’s disease. eNeuro. 2017;4. https://doi.org/10.1523/ENEURO.0149-16.2017.
Kitazawa M, Yamasaki TR, LaFerla FM. Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann N Y Acad Sci. 2004;1035:85–103. https://doi.org/10.1196/annals.1332.006.
Kobayashi S, Ishiguro K, Omori A, Takamatsu M, Arioka M, Imahori K, Uchida T. A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule. FEBS Lett. 1993;335:171–5. https://doi.org/10.1016/0014-5793(93)80723-8.
Kobayashi S, Tanaka T, Soeda Y, Almeida OFX, Takashima A. Local somatodendritic translation and hyperphosphorylation of tau protein triggered by AMPA and NMDA receptor stimulation. EBioMedicine. 2017;20:120–6. https://doi.org/10.1016/j.ebiom.2017.05.012.
Kremer A, Louis JV, Jaworski T, Van Leuven F. GSK3 and Alzheimer’s disease: facts and fiction…. Front Mol Neurosci. 2011;4:17. https://doi.org/10.3389/fnmol.2011.00017.
Kuljiš RO, Salković-Petrišić M. Dementia, diabetes, Alzheimer’s disease, and insulin resistance in the brain: progress, dilemmas, new opportunities, and a hypothesis to tackle intersecting epidemics. J Alzheimers Dis. 2011;25:29–41. https://doi.org/10.3233/JAD-2011-101392.
Kurup P, Zhang Y, Xu J, Venkitaramani DV, Haroutunian V, Greengard P, Nairn AC, Lombroso PJ. Abeta-mediated NMDA receptor endocytosis in Alzheimer’s disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci. 2010;30:5948–57. https://doi.org/10.1523/JNEUROSCI.0157-10.2010.
Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL. Synaptic targeting by Alzheimer’s-related amyloid beta oligomers. J Neurosci. 2004;24:10191–200. https://doi.org/10.1523/JNEUROSCI.3432-04.2004.
Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448–53. https://doi.org/10.1073/pnas.95.11.6448.
Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, Aguzzi A, Lesné SE. The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer’s disease. J Neurosci. 2012;32:16857–16871a. https://doi.org/10.1523/JNEUROSCI.1858-12.2012.
Lee G. Tau and src family tyrosine kinases. Biochim Biophys Acta. 2005;1739:323–30. https://doi.org/10.1016/j.bbadis.2004.09.002.
Lee VM, Balin BJ, Otvos L, Trojanowski JQ. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science. 1991;251:675–8. https://doi.org/10.1126/science.1899488.
Lee B, Cao R, Choi Y-S, Cho H-Y, Rhee AD, Hah CK, Hoyt KR, Obrietan K. The CREB/CRE transcriptional pathway: protection against oxidative stress-mediated neuronal cell death. J Neurochem. 2009;108:1251–65. https://doi.org/10.1111/j.1471-4159.2008.05864.x.
Lee K-I, Lee H-T, Lin H-C, Tsay H-J, Tsai F-C, Shyue S-K, Lee T-S. Role of transient receptor potential ankyrin 1 channels in Alzheimer’s disease. J Neuroinflammation. 2016;13:92. https://doi.org/10.1186/s12974-016-0557-z.
Leonard TA, Hurley JH. Regulation of protein kinases by lipids. Curr Opin Struct Biol. 2011;21:785–91. https://doi.org/10.1016/j.sbi.2011.07.006.
Léveillé F, El Gaamouch F, Gouix E, Lecocq M, Lobner D, Nicole O, Buisson A. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 2008;22:4258–71. https://doi.org/10.1096/fj.08-107268.
Levinthal DJ, DeFranco DB. Transient phosphatidylinositol 3-kinase inhibition protects immature primary cortical neurons from oxidative toxicity via suppression of extracellular signal-regulated kinase activation. J Biol Chem. 2004;279:11206–13. https://doi.org/10.1074/jbc.M314261200.
Li S-T, Ju J-G. Functional roles of synaptic and extrasynaptic NMDA receptors in physiological and pathological neuronal activities. Curr Drug Targets. 2012;13:207–21. https://doi.org/10.2174/138945012799201630.
Li X, Garrity AG, Xu H. Regulation of membrane trafficking by signalling on endosomal and lysosomal membranes. J Physiol Lond. 2013;591:4389–401. https://doi.org/10.1113/jphysiol.2013.258301.
Li C, Zhang N, Hu Y, Wang H. NR2B overexpression leads to the enhancement of specific protein phosphorylation in the brain. Brain Res. 2014;1588:127–34. https://doi.org/10.1016/j.brainres.2014.08.005.
Li B-H, Liao S-Q, Yin Y-W, Long C-Y, Guo L, Cao X-J, Liu Y, Zhou Y, Gao C-Y, Zhang L-L, Li J-C. Telmisartan-induced PPARγ activity attenuates lipid accumulation in VSMCs via induction of autophagy. Mol Biol Rep. 2015;42:179–86. https://doi.org/10.1007/s11033-014-3757-6.
Liang J, Kulasiri D, Samarasinghe S. Computational investigation of Amyloid-β-induced location- and subunit-specific disturbances of NMDAR at hippocampal dendritic spine in Alzheimer’s disease. PLoS One. 2017;12:e0182743. https://doi.org/10.1371/journal.pone.0182743.
Ling X, Martins RN, Racchi M, Craft S, Helmerhorst E. Amyloid beta antagonizes insulin promoted secretion of the amyloid beta protein precursor. J Alzheimers Dis. 2002;4:369–74. https://doi.org/10.3233/jad-2002-4504.
Ling Y, Morgan K, Kalsheker N. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer’s disease. Int J Biochem Cell Biol. 2003;35:1505–35. https://doi.org/10.1016/s1357-2725(03)00133-x.
Liu Y-J, Guo D-W, Tian L, Shang D-S, Zhao W-D, Li B, Fang W-G, Zhu L, Chen Y-H. Peripheral T cells derived from Alzheimer’s disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-alpha-dependent. Neurobiol Aging. 2010;31:175–88. https://doi.org/10.1016/j.neurobiolaging.2008.03.024.
Long KD, Mastropaolo J, Rosse RB, Manaye KF, Deutsch SI. Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB/c mouse strain. Brain Res Bull. 2006;69:626–30. https://doi.org/10.1016/j.brainresbull.2006.03.007.
Louneva N, Cohen JW, Han L-Y, Talbot K, Wilson RS, Bennett DA, Trojanowski JQ, Arnold SE. Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer’s disease. Am J Pathol. 2008;173:1488–95. https://doi.org/10.2353/ajpath.2008.080434.
Lund H, Gustafsson E, Svensson A, Nilsson M, Berg M, Sunnemark D, von Euler G. MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer’s disease granulovacuolar degeneration bodies. Acta Neuropathol Commun. 2014;2:22. https://doi.org/10.1186/2051-5960-2-22.
Ma Q-L, Yang F, Calon F, Ubeda OJ, Hansen JE, Weisbart RH, Beech W, Frautschy SA, Cole GM. p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis. J Biol Chem. 2008;283:14132–43. https://doi.org/10.1074/jbc.M708034200.
Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, Tampellini D, Klann E, Blitzer RD, Gouras GK. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer’s disease. PLoS One. 2010;5:e12845. https://doi.org/10.1371/journal.pone.0012845.
Maiese K. Taking aim at Alzheimer’s disease through the mammalian target of rapamycin. Ann Med. 2014;46:587–96. https://doi.org/10.3109/07853890.2014.941921.
Málaga-Trillo E, Ochs K. Uncontrolled SFK-mediated protein trafficking in prion and Alzheimer’s disease. Prion. 2016;10:352–61. https://doi.org/10.1080/19336896.2016.1221873.
Manolopoulos KN, Klotz L-O, Korsten P, Bornstein SR, Barthel A. Linking Alzheimer’s disease to insulin resistance: the FoxO response to oxidative stress. Mol Psychiatry. 2010;15:1046–52. https://doi.org/10.1038/mp.2010.17.
Matrone C, Ciotti MT, Mercanti D, Marolda R, Calissano P. NGF and BDNF signaling control amyloidogenic route and Abeta production in hippocampal neurons. Proc Natl Acad Sci U S A. 2008;105:13139–44. https://doi.org/10.1073/pnas.0806133105.
McDonald DR, Brunden KR, Landreth GE. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci. 1997;17:2284–94.
Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, Selkoe DJ, Ince PG, Walsh DM, Medical Research Council Cognitive Function and Ageing Study. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain. 2010;133:1328–41. https://doi.org/10.1093/brain/awq065.
Metcalfe C, Bienz M. Inhibition of GSK3 by Wnt signalling--two contrasting models. J Cell Sci. 2011;124:3537–44. https://doi.org/10.1242/jcs.091991.
Michán S, Li Y, Chou MM-H, Parrella E, Ge H, Long JM, Allard JS, Lewis K, Miller M, Xu W, Mervis RF, Chen J, Guerin KI, Smith LEH, McBurney MW, Sinclair DA, Baudry M, de Cabo R, Longo VD. SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci. 2010;30:9695–707. https://doi.org/10.1523/JNEUROSCI.0027-10.2010.
Mizukami K, Abrahamson EE, Mi Z, Ishikawa M, Watanabe K, Kinoshita S, Asada T, Ikonomovic MD. Immunohistochemical analysis of ubiquilin-1 in the human hippocampus: association with neurofibrillary tangle pathology. Neuropathology. 2014;34:11–8. https://doi.org/10.1111/neup.12055.
Mohamed HE, Asker ME, Younis NN, Shaheen MA, Eissa RG. Modulation of brain insulin signaling in Alzheimer’s disease: new insight on the protective role of green coffee bean extract. Nutr Neurosci. 2020;23:27–36. https://doi.org/10.1080/1028415X.2018.1468535.
Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2010;31:224–43. https://doi.org/10.1016/j.neurobiolaging.2008.04.002.
Moravcevic K, Mendrola JM, Schmitz KR, Wang Y-H, Slochower D, Janmey PA, Lemmon MA. Kinase associated-1 domains drive MARK/PAR1 kinases to membrane targets by binding acidic phospholipids. Cell. 2010;143:966–77. https://doi.org/10.1016/j.cell.2010.11.028.
Morel M, Couturier J, Lafay-Chebassier C, Paccalin M, Page G. PKR, the double stranded RNA-dependent protein kinase as a critical target in Alzheimer’s disease. J Cell Mol Med. 2009;13:1476–88. https://doi.org/10.1111/j.1582-4934.2009.00849.x.
Moriwaki K, Chan FK-M. Necroptosis-independent signaling by the RIP kinases in inflammation. Cell Mol Life Sci. 2016;73:2325–34. https://doi.org/10.1007/s00018-016-2203-4.
Morris GP, Clark IA, Vissel B. Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease. Acta Neuropathol. 2018;136:663–89. https://doi.org/10.1007/s00401-018-1918-8.
Mroczko B, Groblewska M, Zboch M, Kulczyńska A, Koper OM, Szmitkowski M, Kornhuber J, Lewczuk P. Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer’s disease. J Alzheimers Dis. 2014;40:351–7. https://doi.org/10.3233/JAD-131634.
Narasimhan K, Govindasamy M, Gauthaman K, Kamal MA, Abuzenadeh AM, Al-Qahtani M, Kanagasabai R. Diabetes of the brain: computational approaches and interventional strategies. CNS Neurol Disord Drug Targets. 2014;13:408–17. https://doi.org/10.2174/18715273113126660156.
Nolt MJ, Lin Y, Hruska M, Murphy J, Sheffler-Colins SI, Kayser MS, Passer J, Bennett MVL, Zukin RS, Dalva MB. EphB controls NMDA receptor function and synaptic targeting in a subunit-specific manner. J Neurosci. 2011;31:5353–64. https://doi.org/10.1523/JNEUROSCI.0282-11.2011.
Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol. 2006;168:184–94. https://doi.org/10.2353/ajpath.2006.050593.
Omkumar RV, Kiely MJ, Rosenstein AJ, Min KT, Kennedy MB. Identification of a phosphorylation site for calcium/calmodulindependent protein kinase II in the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem. 1996;271:31670–8. https://doi.org/10.1074/jbc.271.49.31670.
Ondrejcak T, Klyubin I, Hu N-W, Barry AE, Cullen WK, Rowan MJ. Alzheimer’s disease amyloid beta-protein and synaptic function. NeuroMolecular Med. 2010;12:13–26. https://doi.org/10.1007/s12017-009-8091-0.
Onuki R, Bando Y, Suyama E, Katayama T, Kawasaki H, Baba T, Tohyama M, Taira K. An RNA-dependent protein kinase is involved in tunicamycin-induced apoptosis and Alzheimer’s disease. EMBO J. 2004;23:959–68. https://doi.org/10.1038/sj.emboj.7600049.
Otmakhov N, Tao-Cheng J-H, Carpenter S, Asrican B, Dosemeci A, Reese TS, Lisman J. Persistent accumulation of calcium/calmodulin-dependent protein kinase II in dendritic spines after induction of NMDA receptor-dependent chemical long-term potentiation. J Neurosci. 2004;24:9324–31. https://doi.org/10.1523/JNEUROSCI.2350-04.2004.
Oulès B, Del Prete D, Greco B, Zhang X, Lauritzen I, Sevalle J, Moreno S, Paterlini-Bréchot P, Trebak M, Checler F, Benfenati F, Chami M. Ryanodine receptor blockade reduces amyloid-β load and memory impairments in Tg2576 mouse model of Alzheimer disease. J Neurosci. 2012;32:11820–34. https://doi.org/10.1523/JNEUROSCI.0875-12.2012.
Paccalin M, Pain-Barc S, Pluchon C, Paul C, Besson M-N, Carret-Rebillat A-S, Rioux-Bilan A, Gil R, Hugon J. Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2006;22:320–6. https://doi.org/10.1159/000095562.
Papouin T, Ladépêche L, Ruel J, Sacchi S, Labasque M, Hanini M, Groc L, Pollegioni L, Mothet J-P, Oliet SHR. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell. 2012;150:633–46. https://doi.org/10.1016/j.cell.2012.06.029.
Park H, Kam T-I, Kim Y, Choi H, Gwon Y, Kim C, Koh J-Y, Jung Y-K. Neuropathogenic role of adenylate kinase-1 in Aβ-mediated tau phosphorylation via AMPK and GSK3β. Hum Mol Genet. 2012;21:2725–37. https://doi.org/10.1093/hmg/dds100.
Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T, Matthews P, Isaac JTR, Bortolotto ZA, Wang YT, Collingridge GL. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron. 2007;53:703–17. https://doi.org/10.1016/j.neuron.2007.01.029.
Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, Small S, Spencer B, Rockenstein E, Levine B, Wyss-Coray T. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest. 2008;118:2190–9. https://doi.org/10.1172/JCI33585.
Pozueta J, Lefort R, Shelanski ML. Synaptic changes in Alzheimer’s disease and its models. Neuroscience. 2013;251:51–65. https://doi.org/10.1016/j.neuroscience.2012.05.050.
Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30:1026–36. https://doi.org/10.1016/j.neurobiolaging.2009.04.002.
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9:63–75.e2. https://doi.org/10.1016/j.jalz.2012.11.007.
Pryor PR, Mullock BM, Bright NA, Gray SR, Luzio JP. The role of intraorganellar Ca(2+) in late endosome-lysosome heterotypic fusion and in the reformation of lysosomes from hybrid organelles. J Cell Biol. 2000;149:1053–62. https://doi.org/10.1083/jcb.149.5.1053.
Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem. 1998;273:32730–8. https://doi.org/10.1074/jbc.273.49.32730.
Quiroz-Baez R, Ferrera P, Rosendo-Gutiérrez R, Morán J, Bermúdez-Rattoni F, Arias C. Caspase-12 activation is involved in amyloid-β protein-induced synaptic toxicity. J Alzheimers Dis. 2011;26:467–76. https://doi.org/10.3233/JAD-2011-110326.
Rai S, Kamat PK, Nath C, Shukla R. Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats. Pharmacol Biochem Behav. 2014;117:104–17. https://doi.org/10.1016/j.pbb.2013.11.035.
Rajmohan R, Reddy PH. Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer’s disease neurons. J Alzheimers Dis. 2017;57:975–99. https://doi.org/10.3233/JAD-160612.
Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci. 2009;29:11982–92. https://doi.org/10.1523/JNEUROSCI.3158-09.2009.
Regen F, Hellmann-Regen J, Costantini E, Reale M. Neuroinflammation and Alzheimer’s disease: implications for microglial activation. Curr Alzheimer Res. 2017;14:1140–8. https://doi.org/10.2174/1567205014666170203141717.
Reijerkerk A, Kooij G, van der Pol SMA, Khazen S, Dijkstra CD, de Vries HE. Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain endothelial cells. FASEB J. 2006;20:2550–2. https://doi.org/10.1096/fj.06-6099fje.
Rizzi L, Roriz-Cruz M. Sirtuin 1 and Alzheimer’s disease: An up-to-date review. Neuropeptides. 2018;71:54–60. https://doi.org/10.1016/j.npep.2018.07.001.
Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu G-Q, Palop JJ, Noebels JL, Mucke L. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. J Neurosci. 2011;31:700–11. https://doi.org/10.1523/JNEUROSCI.4152-10.2011.
Rodrigues R, Petersen RB, Perry G. Parallels between major depressive disorder and Alzheimer’s disease: role of oxidative stress and genetic vulnerability. Cell Mol Neurobiol. 2014;34:925–49. https://doi.org/10.1007/s10571-014-0074-5.
Rojas-Fernandez CH, Chen M, Fernandez HL. Implications of amyloid precursor protein and subsequent beta-amyloid production to the pharmacotherapy of Alzheimer’s disease. Pharmacotherapy. 2002;22:1547–63. https://doi.org/10.1592/phco.22.17.1547.34116.
Rosenberger AFN, Morrema THJ, Gerritsen WH, van Haastert ES, Snkhchyan H, Hilhorst R, Rozemuller AJM, Scheltens P, van der Vies SM, Hoozemans JJM. Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer’s disease pathology. J Neuroinflammation. 2016;13:4. https://doi.org/10.1186/s12974-015-0470-x.
Rüb U, Stratmann K, Heinsen H, Seidel K, Bouzrou M, Korf H-W. Alzheimer’s disease: characterization of the brain sites of the initial tau cytoskeletal pathology will improve the success of novel immunological anti-tau treatment approaches. J Alzheimers Dis. 2017;57:683–96. https://doi.org/10.3233/JAD-161102.
Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov. 2007;6:304–12. https://doi.org/10.1038/nrd2272.
Sajan M, Hansen B, Ivey R, Sajan J, Ari C, Song S, Braun U, Leitges M, Farese-Higgs M, Farese RV. Brain insulin signaling is increased in insulin-resistant states and decreases in FOXOs and PGC-1α and increases in Aβ1-40/42 and phospho-tau may abet Alzheimer development. Diabetes. 2016;65:1892–903. https://doi.org/10.2337/db15-1428.
Salminen A, Kaarniranta K, Kauppinen A, Ojala J, Haapasalo A, Soininen H, Hiltunen M. Impaired autophagy and APP processing in Alzheimer’s disease: the potential role of Beclin 1 interactome. Prog Neurobiol. 2013;106–107:33–54. https://doi.org/10.1016/j.pneurobio.2013.06.002.
Santos LE, Beckman D, Ferreira ST. Microglial dysfunction connects depression and Alzheimer’s disease. Brain Behav Immun. 2016;55:151–65. https://doi.org/10.1016/j.bbi.2015.11.011.
Sato S, Xu J, Okuyama S, Martinez LB, Walsh SM, Jacobsen MT, Swan RJ, Schlautman JD, Ciborowski P, Ikezu T. Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1. J Neurosci. 2008;28:14511–21. https://doi.org/10.1523/JNEUROSCI.3417-08.2008.
Scali C, Caraci F, Gianfriddo M, Diodato E, Roncarati R, Pollio G, Gaviraghi G, Copani A, Nicoletti F, Terstappen GC, Caricasole A. Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1. Neurobiol Dis. 2006;24:254–65. https://doi.org/10.1016/j.nbd.2006.06.016.
Schuh AF, Rieder CM, Rizzi L, Chaves M, Roriz-Cruz M. Mechanisms of brain aging regulation by insulin: implications for neurodegeneration in late-onset Alzheimer’s disease. ISRN Neurol. 2011;2011:306905. https://doi.org/10.5402/2011/306905.
Schulingkamp RJ, Pagano TC, Hung D, Raffa RB. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev. 2000;24:855–72.
Schutters K, Reutelingsperger C. Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis. 2010;15:1072–82. https://doi.org/10.1007/s10495-010-0503-y.
Seixas da Silva GS, Melo HM, Lourenco MV, Lyra E Silva NM, de Carvalho MB, Alves-Leon SV, de Souza JM, Klein WL, da-Silva WS, Ferreira ST, De Felice FG. Amyloid-β oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons. J Biol Chem. 2017;292:7395–406. https://doi.org/10.1074/jbc.M116.753525.
Selkoe DJ. Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis. 2001;3:75–80. https://doi.org/10.3233/jad-2001-3111.
Sepulveda FJ, Parodi J, Peoples RW, Opazo C, Aguayo LG. Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS One. 2010;5:e11820. https://doi.org/10.1371/journal.pone.0011820.
Shahani N, Pryor W, Swarnkar S, Kholodilov N, Thinakaran G, Burke RE, Subramaniam S. Rheb GTPase regulates β-secretase levels and amyloid β generation. J Biol Chem. 2014;289:5799–808. https://doi.org/10.1074/jbc.M113.532713.
Shang YC, Chong ZZ, Hou J, Maiese K. The forkhead transcription factor FOXO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Curr Neurovasc Res. 2009;6:20–31. https://doi.org/10.2174/156720209787466064.
Shang YC, Chong ZZ, Wang S, Maiese K. Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia. Curr Neurovasc Res. 2011;8:270–85. https://doi.org/10.2174/156720211798120990.
Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837–42. https://doi.org/10.1038/nm1782.
Sheffler-Collins SI, Dalva MB. EphBs: an integral link between synaptic function and synaptopathies. Trends Neurosci. 2012;35:293–304. https://doi.org/10.1016/j.tins.2012.03.003.
Shi J, Johansson J, Woodling NS, Wang Q, Montine TJ, Andreasson K. The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol. 2010;184:7207–18. https://doi.org/10.4049/jimmunol.0903487.
Shi X-D, Sun K, Hu R, Liu X-Y, Hu Q-M, Sun X-Y, Yao B, Sun N, Hao J-R, Wei P, Han Y, Gao C. Blocking the interaction between EphB2 and ADDLs by a small peptide rescues impaired synaptic plasticity and memory deficits in a mouse model of Alzheimer’s disease. J Neurosci. 2016;36:11959–73. https://doi.org/10.1523/JNEUROSCI.1327-16.2016.
Simón AM, de Maturana RL, Ricobaraza A, Escribano L, Schiapparelli L, Cuadrado-Tejedor M, Pérez-Mediavilla A, Avila J, Del Río J, Frechilla D. Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer’s disease. J Alzheimers Dis. 2009;17:773–86. https://doi.org/10.3233/JAD-2009-1096.
Singh AK, Kashyap MP, Tripathi VK, Singh S, Garg G, Rizvi SI. Neuroprotection through rapamycin-induced activation of autophagy and PI3K/Akt1/mTOR/CREB signaling against amyloid-β-induced oxidative stress, synaptic/neurotransmission dysfunction, and neurodegeneration in adult rats. Mol Neurobiol. 2017;54:5815–28. https://doi.org/10.1007/s12035-016-0129-3.
Singh A, Hasan A, Tiwari S, Pandey LM. Therapeutic advancement in Alzheimer disease: new hopes on the horizon? CNS Neurol Disord Drug Targets. 2018;17:571–89. https://doi.org/10.2174/1871527317666180627122448.
Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051–8. https://doi.org/10.1038/nn1503.
Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease--is this type 3 diabetes? J Alzheimers Dis. 2005;7:63–80.
Steinerman JR, Irizarry M, Scarmeas N, Raju S, Brandt J, Albert M, Blacker D, Hyman B, Stern Y. Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch Neurol. 2008;65:906–12. https://doi.org/10.1001/archneur.65.7.906.
St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127:397–408. https://doi.org/10.1016/j.cell.2006.09.024.
Suemoto CK, Ferretti-Rebustini REL, Rodriguez RD, Leite REP, Soterio L, Brucki SMD, Spera RR, Cippiciani TM, Farfel JM, Chiavegatto Filho A, Naslavsky MS, Zatz M, Pasqualucci CA, Jacob-Filho W, Nitrini R, Grinberg LT. Neuropathological diagnoses and clinical correlates in older adults in Brazil: a cross-sectional study. PLoS Med. 2017;14:e1002267. https://doi.org/10.1371/journal.pmed.1002267.
Sun X-Y, Tuo Q-Z, Liuyang Z-Y, Xie A-J, Feng X-L, Yan X, Qiu M, Li S, Wang X-L, Cao F-Y, Wang X-C, Wang J-Z, Liu R. Extrasynaptic NMDA receptor-induced tau overexpression mediates neuronal death through suppressing survival signaling ERK phosphorylation. Cell Death Dis. 2016;7:e2449. https://doi.org/10.1038/cddis.2016.329.
Sun Y, Xiao Q, Luo C, Zhao Y, Pu D, Zhao K, Chen J, Wang M, Liao Z. High-glucose induces tau hyperphosphorylation through activation of TLR9-P38MAPK pathway. Exp Cell Res. 2017;359:312–8. https://doi.org/10.1016/j.yexcr.2017.07.032.
Swaminathan G, Zhu W, Plowey ED. BECN1/Beclin 1 sorts cell-surface APP/amyloid β precursor protein for lysosomal degradation. Autophagy. 2016;12:2404–19. https://doi.org/10.1080/15548627.2016.1234561.
Sze C, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ. N-Methyl-D-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer’s disease. J Neurol Sci. 2001;182:151–9. https://doi.org/10.1016/s0022-510x(00)00467-6.
Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK. Co-occurrence of Alzheimer’s disease ß-amyloid and τ pathologies at synapses. Neurobiol Aging. 2010;31:1145–52. https://doi.org/10.1016/j.neurobiolaging.2008.07.021.
Takahashi RH, Nagao T, Gouras GK. Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer’s disease. Pathol Int. 2017;67:185–93. https://doi.org/10.1111/pin.12520.
Takasu MA, Dalva MB, Zigmond RE, Greenberg ME. Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors. Science. 2002;295:491–5. https://doi.org/10.1126/science.1065983.
Talbot K, Wang H-Y. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer’s disease. Alzheimers Dement. 2014;10:S12–25. https://doi.org/10.1016/j.jalz.2013.12.007.
Talbot K, Wang H-Y, Kazi H, Han L-Y, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122:1316–38. https://doi.org/10.1172/JCI59903.
Tampellini D, Rahman N, Gallo EF, Huang Z, Dumont M, Capetillo-Zarate E, Ma T, Zheng R, Lu B, Nanus DM, Lin MT, Gouras GK. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci. 2009;29:9704–13. https://doi.org/10.1523/JNEUROSCI.2292-09.2009.
Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ. Role of CD40 ligand in amyloidosis in transgenic Alzheimer’s mice. Nat Neurosci. 2002;5:1288–93. https://doi.org/10.1038/nn968.
Tan B, Choi RH, Chin TJY, Kaur C, Ling E-A. Manipulation of microglial activity as a therapy for Alzheimer’s disease. Front Biosci (Schol Ed). 2012;4:1402–12. https://doi.org/10.2741/s342.
Tang Z, Bereczki E, Zhang H, Wang S, Li C, Ji X, Branca RM, Lehtiö J, Guan Z, Filipcik P, Xu S, Winblad B, Pei J-J. Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease. J Biol Chem. 2013;288:15556–70. https://doi.org/10.1074/jbc.M112.435123.
Tapia-Rojas C, Inestrosa NC. Loss of canonical Wnt signaling is involved in the pathogenesis of Alzheimer’s disease. Neural Regen Res. 2018;13:1705–10. https://doi.org/10.4103/1673-5374.238606.
Tapia-Rojas C, Burgos PV, Inestrosa NC. Inhibition of Wnt signaling induces amyloidogenic processing of amyloid precursor protein and the production and aggregation of Amyloid-β (Aβ)42 peptides. J Neurochem. 2016;139:1175–91. https://doi.org/10.1111/jnc.13873.
Teng FYH, Tang BL. NF-kappaB signaling in neurite growth and neuronal survival. Rev Neurosci. 2010;21:299–313. https://doi.org/10.1515/revneuro.2010.21.4.299.
Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572–80. https://doi.org/10.1002/ana.410300410.
Thal DR, Del Tredici K, Ludolph AC, Hoozemans JJM, Rozemuller AJ, Braak H, Knippschild U. Stages of granulovacuolar degeneration: their relation to Alzheimer’s disease and chronic stress response. Acta Neuropathol. 2011;122:577–89. https://doi.org/10.1007/s00401-011-0871-6.
Tian L, Stefanidakis M, Ning L, Van Lint P, Nyman-Huttunen H, Libert C, Itohara S, Mishina M, Rauvala H, Gahmberg CG. Activation of NMDA receptors promotes dendritic spine development through MMP-mediated ICAM-5 cleavage. J Cell Biol. 2007;178:687–700. https://doi.org/10.1083/jcb.200612097.
Togo T, Akiyama H, Iseki E, Kondo H, Ikeda K, Kato M, Oda T, Tsuchiya K, Kosaka K. Occurrence of T cells in the brain of Alzheimer’s disease and other neurological diseases. J Neuroimmunol. 2002;124:83–92. https://doi.org/10.1016/s0165-5728(01)00496-9.
Tsai C-Y, Chan JYH, Hsu K, Chang AYW, Chan SHH. Brain-derived neurotrophic factor ameliorates brain stem cardiovascular dysregulation during experimental temporal lobe status epilepticus. PLoS One. 2012;7:e33527. https://doi.org/10.1371/journal.pone.0033527.
Tung Y-T, Wang B-J, Hu M-K, Hsu W-M, Lee H, Huang W-P, Liao Y-F. Autophagy: a double-edged sword in Alzheimer’s disease. J Biosci. 2012;37:157–65. https://doi.org/10.1007/s12038-011-9176-0.
Utton MA, Vandecandelaere A, Wagner U, Reynolds CH, Gibb GM, Miller CC, Bayley PM, Anderton BH. Phosphorylation of tau by glycogen synthase kinase 3beta affects the ability of tau to promote microtubule self-assembly. Biochem J. 1997;323(Pt 3):741–7. https://doi.org/10.1042/bj3230741.
Vallée A, Lecarpentier Y, Guillevin R, Vallée J-N. Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer’s disease. Acta Biochim Biophys Sin Shanghai. 2017;49:853–66. https://doi.org/10.1093/abbs/gmx073.
van der Harg JM, Eggels L, Bangel FN, Ruigrok SR, Zwart R, Hoozemans JJM, la Fleur SE, Scheper W. Insulin deficiency results in reversible protein kinase A activation and tau phosphorylation. Neurobiol Dis. 2017;103:163–73. https://doi.org/10.1016/j.nbd.2017.04.005.
Venugopal B, Mesires NT, Kennedy JC, Curcio-Morelli C, Laplante JM, Dice JF, Slaugenhaupt SA. Chaperone-mediated autophagy is defective in mucolipidosis type IV. J Cell Physiol. 2009;219:344–53. https://doi.org/10.1002/jcp.21676.
Verslegers M, Lemmens K, Van Hove I, Moons L. Matrix metalloproteinase-2 and -9 as promising benefactors in development, plasticity and repair of the nervous system. Prog Neurobiol. 2013;105:60–78. https://doi.org/10.1016/j.pneurobio.2013.03.004.
Vilalta A, Brown GC. Neurophagy, the phagocytosis of live neurons and synapses by glia, contributes to brain development and disease. FEBS J. 2018;285:3566–75. https://doi.org/10.1111/febs.14323.
Villemagne VL, Rowe CC. Long night’s journey into the day: amyloid-β imaging in Alzheimer’s disease. J Alzheimers Dis. 2013;33(Suppl 1):S349–59. https://doi.org/10.3233/JAD-2012-129034.
Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14:225–36. https://doi.org/10.1038/nrneurol.2018.9.
Wang Z, Yang L, Zheng H. Role of APP and Aβ in synaptic physiology. Curr Alzheimer Res. 2012;9:217–26. https://doi.org/10.2174/156720512799361691.
Wang C-M, Liu M-Y, Wang F, Wei M-J, Wang S, Wu C-F, Yang J-Y. Anti-amnesic effect of pseudoginsenoside-F11 in two mouse models of Alzheimer’s disease. Pharmacol Biochem Behav. 2013;106:57–67. https://doi.org/10.1016/j.pbb.2013.03.010.
Wang X, Li G-J, Hu H-X, Ma C, Ma D-H, Liu X-L, Jiang X-M. Cerebral mTOR signal and pro-inflammatory cytokines in Alzheimer’s disease rats. Transl Neurosci. 2016;7:151–7. https://doi.org/10.1515/tnsci-2016-0022.
Wang B-J, Her GM, Hu M-K, Chen Y-W, Tung Y-T, Wu P-Y, Hsu W-M, Lee H, Jin L-W, Hwang S-PL, Chen RP-Y, Huang C-J, Liao Y-F. ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2017;114:E3129–38. https://doi.org/10.1073/pnas.1618804114.
Weisman D, Hakimian E, Ho GJ. Interleukins, inflammation, and mechanisms of Alzheimer’s disease. Vitam Horm. 2006;74:505–30. https://doi.org/10.1016/S0083-6729(06)74020-1.
Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep. 2007;7:373–80. https://doi.org/10.1007/s11910-007-0058-7.
Wilcock GK. Memantine for the treatment of dementia. Lancet Neurol. 2003;2:503–5. https://doi.org/10.1016/s1474-4422(03)00486-1.
Wilkinson B, Koenigsknecht-Talboo J, Grommes C, Lee CYD, Landreth G. Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J Biol Chem. 2006;281:20842–50. https://doi.org/10.1074/jbc.M600627200.
Willén K, Sroka A, Takahashi RH, Gouras GK. Heterogeneous Association of Alzheimer’s disease-linked Amyloid-β and Amyloid-β protein precursor with synapses. J Alzheimers Dis. 2017;60:511–24. https://doi.org/10.3233/JAD-170262.
Williamson R, Usardi A, Hanger DP, Anderton BH. Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism. FASEB J. 2008;22:1552–9. https://doi.org/10.1096/fj.07-9766com.
Woltjer RL, Maezawa I, Ou JJ, Montine KS, Montine TJ. Advanced glycation endproduct precursor alters intracellular amyloid-beta/A beta PP carboxy-terminal fragment aggregation and cytotoxicity. J Alzheimers Dis. 2003;5:467–76. https://doi.org/10.3233/jad-2003-5607.
Woodling NS, Wang Q, Priyam PG, Larkin P, Shi J, Johansson JU, Zagol-Ikapitte I, Boutaud O, Andreasson KI. Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J Neurosci. 2014;34:5882–94. https://doi.org/10.1523/JNEUROSCI.0410-14.2014.
Wu C-L, Hwang C-S, Chen S-D, Yin J-H, Yang D-I. Neuroprotective mechanisms of brain-derived neurotrophic factor against 3-nitropropionic acid toxicity: therapeutic implications for Huntington’s disease. Ann N Y Acad Sci. 2010;1201:8–12. https://doi.org/10.1111/j.1749-6632.2010.05628.x.
Xie Z, Klionsky DJ. Autophagosome formation: core machinery and adaptations. Nat Cell Biol. 2007;9:1102–9. https://doi.org/10.1038/ncb1007-1102.
Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R. Alzheimer’s beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci. 2002;22:RC221. 20026383.
Xu H, Sweeney D, Wang R, Thinakaran G, Lo AC, Sisodia SS, Greengard P, Gandy S. Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proc Natl Acad Sci U S A. 1997;94:3748–52. https://doi.org/10.1073/pnas.94.8.3748.
Yang K, Belrose J, Trepanier CH, Lei G, Jackson MF, MacDonald JF. Fyn, a potential target for Alzheimer’s disease. J Alzheimers Dis. 2011;27:243–52. https://doi.org/10.3233/JAD-2011-110353.
Yin Y, Zhao Y, Han S, Zhang N, Chen H, Wang X. Autophagy-ERK1/2-involved disinhibition of hippocampal neurons contributes to the pre-synaptic toxicity induced by Aβ42 exposure. J Alzheimers Dis. 2017;59:851–69. https://doi.org/10.3233/JAD-170246.
Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee J-H, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y, Duff K, Uchiyama Y, Näslund J, Mathews PM, Cataldo AM, Nixon RA. Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer’s disease. J Cell Biol. 2005;171:87–98. https://doi.org/10.1083/jcb.200505082.
Yu L, McPhee CK, Zheng L, Mardones GA, Rong Y, Peng J, Mi N, Zhao Y, Liu Z, Wan F, Hailey DW, Oorschot V, Klumperman J, Baehrecke EH, Lenardo MJ. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature. 2010;465:942–6. https://doi.org/10.1038/nature09076.
Yu Z, Dou F, Wang Y, Hou L, Chen H. Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling. J Neuroinflammation. 2018;15:316. https://doi.org/10.1186/s12974-018-1351-x.
Yue X, Dreyfus C, Kong TA-N, Zhou R. A subset of signal transduction pathways is required for hippocampal growth cone collapse induced by ephrin-A5. Dev Neurobiol. 2008;68:1269–86. https://doi.org/10.1002/dneu.20657.
Zachari M, Ganley IG. The mammalian ULK1 complex and autophagy initiation. Essays Biochem. 2017;61:585–96. https://doi.org/10.1042/EBC20170021.
Zhang YY, Yang LQ, Guo LM. Effect of phosphatidylserine on memory in patients and rats with Alzheimer’s disease. Genet Mol Res. 2015;14:9325–33. https://doi.org/10.4238/2015.August.10.13.
Zhang L, Fang Y, Cheng X, Lian Y, Xu H, Zeng Z, Zhu H. TRPML1 participates in the progression of Alzheimer’s disease by regulating the PPARγ/AMPK/Mtor signalling pathway. Cell Physiol Biochem. 2017;43:2446–56. https://doi.org/10.1159/000484449.
Zhang N, Parr CJC, Birch AM, Goldfinger MH, Sastre M. The amyloid precursor protein binds to β-catenin and modulates its cellular distribution. Neurosci Lett. 2018a;685:190–5. https://doi.org/10.1016/j.neulet.2018.08.044.
Zhang Y, Huang N-Q, Yan F, Jin H, Zhou S-Y, Shi J-S, Jin F. Diabetes mellitus and Alzheimer’s disease: GSK-3β as a potential link. Behav Brain Res. 2018b;339:57–65. https://doi.org/10.1016/j.bbr.2017.11.015.
Zhao L, Ma Q-L, Calon F, Harris-White ME, Yang F, Lim GP, Morihara T, Ubeda OJ, Ambegaokar S, Hansen JE, Weisbart RH, Teter B, Frautschy SA, Cole GM. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci. 2006;9:234–42. https://doi.org/10.1038/nn1630.
Zhao W-Q, Lacor PN, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric A{beta}. J Biol Chem. 2009;284:18742–53. https://doi.org/10.1074/jbc.M109.011015.
Zhong W, Yamagata HD, Taguchi K, Akatsu H, Kamino K, Yamamoto T, Kosaka K, Takeda M, Kondo I, Miki T. Lymphocyte-specific protein tyrosine kinase is a novel risk gene for Alzheimer disease. J Neurol Sci. 2005;238:53–7. https://doi.org/10.1016/j.jns.2005.06.017.
Zhu Z, Yan J, Jiang W, Yao X, Chen J, Chen L, Li C, Hu L, Jiang H, Shen X. Arctigenin effectively ameliorates memory impairment in Alzheimer’s disease model mice targeting both β-amyloid production and clearance. J Neurosci. 2013;33:13138–49. https://doi.org/10.1523/JNEUROSCI.4790-12.2013.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Engin, A.B., Engin, A. (2021). Alzheimer’s Disease and Protein Kinases. In: Engin, A.B., Engin, A. (eds) Protein Kinase-mediated Decisions Between Life and Death. Advances in Experimental Medicine and Biology, vol 1275. Springer, Cham. https://doi.org/10.1007/978-3-030-49844-3_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-49844-3_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-49843-6
Online ISBN: 978-3-030-49844-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)